PF-03654746

DB12201InvestigationalSmall molecule

PF-03654746 has been investigated for the treatment of Narcolepsy, Schizophrenia, Tourette's Syndrome, and Excessive Daytime Sleepiness.

Chemical structure of PF-03654746
Mechanism
Curator reviewed
Formula / weight
C18H24F2N2O · 322.4 g/mol (avg)
Code names
PF 03654746

Resolves to

Compound
UNIIG3QE979K1XCAS935840-31-6ChEMBLCHEMBL2151197PubChem16119086
Structure
InChIKeySXMBKHYDZOCBMT-PPUGGXLSSA-NSMILESCCNC(=O)[C@H]1C[C@](F)(C1)C1=CC(F)=C(CN2CCCC2)C=C1
Targets
Q9Y5N1HRH3

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
7Clinical trialsPhase, status and sponsor resolved per trial
Sign in
3+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with PF-03654746, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In